D E Nelson
1 Haskovee L. L’akathisie, Rev. NeuroL(Paris) 1909; 9: 1107-9.
2 Halstead S.M, Barnes TRE & Speller JC Akathisia : prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry. 1994; 164: 177-183.
3 Chung W.S.D. & Chin HFK Drug induced akathisia revisited BrJ Clin Psychiatry. 1996; 50 (5): 270-278.
4 Blaisdell G.D. Akathisia: A comprehensive review and treatment summary. Pharmacopsychiatry 1994; 27: 139-146.
5 Kasantikul D.. Drug induced akathisia and suicidal tendencies in psychotic patients. J Med AY.Yoc Thai. 1998; 81(7): 551-4.
6 Drake R.E & Erlich J. Suicide attempts associated with akathisia. Am J Psychiatry. 1985; 142(4): 499-501.
7 Barnes TRE A rating scale for drug induced akathisia. Br J Psychiatry 1989; 1.54: 672-6.
8 Sachdev P.. The epidemiology of drug induced akathisia: Part i. Acute akathisia. Schizophr Bull. 1995; 21(3): 431-449.8
9 Sachdev P. & Kmk J. Clinical characteristics and predisposing factors in acute drug induced akathisia. Arch Gen Psychiatry. 1994; 51: 963-974.
10 Miller CAL & Fleisthacker W.W. Managing antipsychotic induced acute and chronic akathisia. Drugsqf 2000; 22(l): 73-81.
11 Sachdev P. The epidemiology of drug induced akathisia: Part II. Chronic, tardive and withdrawal akathisias. Schizophr Bull. 1995; 21(3): 451-460.
12 Farde L, Norstrom XL, Weisel F.A. etal Positron emission tomographic analysis of central D 1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49: 538-544.
13 Cohen ILM, Keek P.L Sattin A. & Colt J.0. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry. 1991; 29: 1215-1219.
14 Ekbom, K.A. Restless legs syndrome. 1960; Neurol, 10, 868-873.
15 Barnes TRE. & Braude W.M. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874-879.
16 Claghorn J, Honigteld G, Abumbah F.S. et al The risks and benefits of clozapine verses chlorpromazine. J chn psychopharmacol 1987; 7: 377-384.
17 Sandoz Pharmaceutical Corporation. Hospital Pharmacists Guide to the Clozaril Patient Management System. E. Rutherford, N.J. Sandoz.
18 Safferman A.4 Lieberman 1A, Pollack S. etaL (1992).Clozapine and akathisia. Biol Psychiatry. 1991; 31: 753-754.
19 Miller CM, Molir F, Umbricht D. et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapme, risperidone, and conventional antipsychotics. J Clinical Psychiatry. 1998; 59(2): 69-75.
20 Taylor D, McConnell H, McConnell D, et al. Maudsley prescribing guidelines. 6th edition. Martui Dunitz. London 2001.
21 Weiss D, Aizeaberg D, Hermesh 11, et al . Cyprobeptadine treatment in neuroleptic induced akathisia. Br J Psychiatry. 1995; 167(4): 483 -6.
22 Poyurovsky M, Shardorodsky M, Fuchs C, Schneidinan M. & Weizman A. Treatment of neuroleptic induced akathisia with the SHT2 antagonist mianserin. Br J Psychiatry. 1999; 174: 238-242.
23 Anfang MK.& Pope HG. Treatment of neuroleptic: induced akathisia with nicotine patches. P.Pychopharmacology. 1997; 134(2): 153-6.